Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.64 |
| ▸ | SCD | O00767 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18863621 | 1.00 | RIPK1 (0.64) | RIPK1SCDPIK3CDKMT2AMEN1 | |
| SCHEMBL4070782 | 1.00 | RIPK1 (0.64) | RIPK1SCDPIK3CDKMT2AMEN1 | |
| SCHEMBL2237484 | 0.83 | PIK3CD (0.48) | RIPK1SCDPIK3CD | |
| SCHEMBL16401399 | 0.83 | RIPK1 (0.50) | RIPK1POLB | |
| SCHEMBL4657693 | 0.83 | RIPK1 (0.47) | RIPK1SCDKMT2AMEN1POLB | |
| SCHEMBL4657697 | 0.83 | RIPK1 (0.47) | RIPK1SCDKMT2AMEN1POLB | |
| SCHEMBL19217395 | 0.81 | RIPK1 (0.59) | RIPK1SCDPIK3CDKMT2AMEN1 | |
| SCHEMBL19217168 | 0.81 | RIPK1 (0.59) | RIPK1SCDPIK3CDKMT2AMEN1 | |
| SCHEMBL29082367 | 0.80 | RIPK1 (0.48) | RIPK1SCDPOLB | |
| SCHEMBL29082368 | 0.80 | RIPK1 (0.48) | RIPK1SCDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515724-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1664026-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7465746-B2 | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP | MERCK & CO., INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7348440-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1551962-A4 | MITOTIC KINESIN BINDING SITE | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060234984-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. | 2006-10-19 | — | — | US | disclosed |
| US-20060134767-A1 | Mitotic kinesin binding site | MERCK & CO., INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1664026-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060105997-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
| EP-1515724-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1551962-A2 | MITOTIC KINESIN BINDING SITE | Merck & Co., Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1515724-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2005019206-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043357-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-02-24 | — | — | US | disclosed |
| US-20050038074-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2004087050-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004004652-A2 | MITOTIC KINESIN BINDING SITE | MERCK & CO., INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003105855-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234984-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | KIF5B, KIF2C, KIF5C | RIPK1 3658/4885SCD 3648/4885PIK3CD 690/4885 |
| US-20050043357-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | RIPK1 2607/4885SCD 3572/4885PIK3CD 664/4885 |
| US-20060105997-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | RIPK1 2607/4885SCD 3559/4885PIK3CD 719/4885 |
| US-20050038074-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | RIPK1 2607/4885SCD 3572/4885PIK3CD 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.